TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01338025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART regimen
Description: The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC or FTC monotherapy
Description: The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
Study: NCT01427231

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose
Description: The effect of a glucose solution on cognitive performance will be measured.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sacharose
Description: The effect of a sacharose solution on cognitive performance will be measured.
Study: NCT00636649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10-20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06723873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping
Description: The treatment group received Kinesiology Taping around the trunk extensors, lower and middle trapezius, supraspinatus, deltoid muscle group, and serratus anterior muscle.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Kinesio Taping
Description: In the control group, kinesiology tape was applied without tension and in a manner that did not target specific muscle groups or respect the anatomical origin and insertion points.
Study: NCT06733961

Intervention type: DIAGNOSTIC_TEST
Intervention: SCUBE-1 and VAP-1
Description: There is no other study comparing these biomarkers with healthy volunteers in the diagnosis of pulmonary embolism.

Intervention type: DIAGNOSTIC_TEST
Intervention: SCUBE-1 and VAP-1
Description: There is no other study comparing these biomarkers with healthy volunteers in the diagnosis of pulmonary embolism.
Study: NCT01464164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept with prednisone boost
Description: Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg).
Study: NCT02529046

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CLA
Description: CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group received 4 g/day of olive oil. Aerobic exercise
Study: NCT01427231

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The effect of a placebo drink with sweeteners on cognitive performance will be measured.
Study: NCT01631799

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral catheter
Description: Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
Study: NCT02800135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
Study: NCT01808781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises plus walking program
Description: Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become somewhat active or active by the end of the 8-week intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking only program
Description: Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
Study: NCT02412163

Intervention type: DEVICE
Intervention: Ellipse IM HTO Nail
Study: NCT02650401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entrectinib
Description: TRKA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entrectinib
Description: TRKA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entrectinib
Description: TRKA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entrectinib
Description: TRKA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entrectinib
Description: TRKA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entrectinib
Description: TRKA/B/C, ROS1, and ALK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entrectinib
Description: TRKA/B/C, ROS1, and ALK inhibitor
Study: NCT04487093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoantigen vaccine + EGFR-TKI
Description: Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks.~The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoantigen vaccine + anti-angioge
Description: neoantigen vaccine + anti-angioge
Study: NCT03872921

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: norUrsodeoxycholic Acid
Description: oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norUrsodeoxycholic Acid
Description: oral treatment
Study: NCT00808379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.

Intervention type: RADIATION
Group type: OTHER
Intervention: Additional Radiation boost to the primary tumor volume
Description: 15-20Gy
Study: NCT04133155

Intervention type: DRUG
Intervention: nab paclitaxel plus gemcitabine
Description: Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
Study: NCT04081467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: 10-day of complete bed rest
Study: NCT04450264

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: African Immigrant Breast Cancer Education Program
Description: African immigrant women are at significant risk for not participating in preventive screening, such as for breast cancer. Thus, this project will culturally adapt an existing evidenced-based, the Witness Project, by identifying potential barriers and guided by the Health Belief Model incorporate those findings into a group-based narrative education program for English and French-speaking African immigrant women. The program content will include: (1) information about the benefits of early detection of breast cancer screening, (2) education about disparities in breast cancer, (3) disparities in breast cancer screening among African immigrant women, and (4) will address the unique barriers and facilitators of African immigrant women identified in Aim 1 of this study. The program will use a culturally matched peer approach to educate and model successful experiences with mammography screening.
Study: NCT01738984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MomZing Web Program
Description: Online web platform that is accessed via a television connected to internet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise DVD
Description: Standard exercise DVD that demonstrates exercises a women does with an infant.
Study: NCT02306070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin treatment + standard of care dietary and exercise advice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No metformin treatment
Description: no metformin treatment + standard of care dietary and exercise advice
Study: NCT02646228

Intervention type: OTHER
Intervention: molecular profiling, patient derived cells
Description: molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer.
Study: NCT00221442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: zonegran (zonisamide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: fake pill
Study: NCT02801994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAV, Puritan Bennett 980 ventilator
Description: The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
Study: NCT03034642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with bilateral bronchoalveolar lavages
Description: Bronchoscopy with bilateral bronchoalveolar lavages
Study: NCT01262287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules in same number as active drug, daily for 8-week treatment period
Study: NCT03721263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASLAN004
Description: Single Dose
Study: NCT00441129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimed paradigm Real Time Sytem
Description: Minimed paradigm Real Time Sytem

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimed Paradigm 512/712 Insulin pump
Description: Minimed Paradigm 512/712 Insulin pump
Study: NCT04339101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given via infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib Adipate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03457753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole Oral Soluble Film
Description: Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
Study: NCT01092338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vit D3)
Description: To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vit D3)
Description: To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
Study: NCT02597400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: * Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: * Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~* HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals.
Study: NCT00109291

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study: NCT03786731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
Study: NCT02351804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + dexamethasone
Description: Adductor canal block, single bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine + placebo
Description: Adductor canal block, single bolus
Study: NCT03545867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated control (CON)
Description: Seated rest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous (MICT)
Description: Arm cycling at a continuous power output

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Arm cycling at power outputs that vary between high and low intensity intervals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT)
Description: Alternating between six upper extremity resistance maneuvers interspersed with low-resistance/high-speed arm cycling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid Meal
Description: A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid Meal
Description: A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid Meal
Description: A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid Meal
Description: A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
Study: NCT00372281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cliavist
Description: Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight \> 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
Study: NCT03317002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: Oral dose of AZD5718 (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: Oral dose of AZD5718 (tablet)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (tablet)
Study: NCT01602887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-0332991
Description: isethionate hard capsule, 125 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: freebase hard capsule with a small particle size, 125 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: freebase hard capsule with a large particle size, 125 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: oral solution, 50 mg, single dose
Study: NCT04339101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT03692533

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immunohistochemistry
Description: Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immunohistochemistry
Description: Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case.
Study: NCT03263429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutaminase Inhibitor CB-839
Description: Given by mouth

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride (phase I only)
Description: Given by vein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans
Description: During phase II at baseline and day 28 of cycle 1
Study: NCT02392013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Modification
Description: Removal of home barriers or hazards.
Study: NCT00436657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHPP of Cisplatin
Description: Starting dose of 100 mg/m\^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Surgery
Description: Surgical removal of abdominal tumors.
Study: NCT03783182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethason Sodium Phosphate
Description: Glucocorticoid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10% glucose solution
Description: Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
Study: NCT03556111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sticky bone augmentation
Description: 1. Autogenous sticky bone augmentation for the first group~2. Autogenous sticky bone preparation with xenograft usage~3. After 5-month of bone grafting; esthetic implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sticky bone augmentation
Description: 1. Autogenous sticky bone augmentation for the first group~2. Autogenous sticky bone preparation with xenograft usage~3. After 5-month of bone grafting; esthetic implant placement
Study: NCT02219048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 680 micrograms BID, Orally inhaled placebo for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03715455
Description: 680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
Study: NCT03876834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory training
Description: Respiratory training was done by using threshold inspiratory muscle trainer(Respironics, New Jersey , USA, No.8373-0730)
Study: NCT04339101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO